Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACITAC-001: Hybrid Type Two Implementation Study of CAR-T Therapy in Colombia Based on a Pilot Clinical Trial ARI-0001 T Cells With Anti-CD19 Chimeric Antigen Receptor (CAR-T) for the Treatment of Recurrent/Refractory CD19+ Hematolymphoid Neoplasms.

NCT07412405 is registered in ClinicalTrials.gov with GUSTAVO SALGUERO as lead sponsor.

NCT NCT07412405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07412405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACITAC-001: Hybrid Type Two Implementation Study of CAR-T Therapy in Colombia Based on a Pilot Clinical Trial ARI-0001 T Cells With Anti-CD19 Chimeric Antigen Receptor (CAR-T) for the Treatment of Recurrent/Refractory CD19+ Hematolymphoid Neoplasms.
Lead sponsor
GUSTAVO SALGUERO
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2029
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adult b-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl)